Enlivex Therapeutics Price To Book vs. Debt To Equity
| ENLV Stock | ILA 415.10 4.10 0.98% |
For Enlivex Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Enlivex Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Enlivex Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Enlivex Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Enlivex Therapeutics over time as well as its relative position and ranking within its peers.
Enlivex |
Enlivex Therapeutics Debt To Equity vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Enlivex Therapeutics's current stock value. Our valuation model uses many indicators to compare Enlivex Therapeutics value to that of its competitors to determine the firm's financial worth. Enlivex Therapeutics is one of the top stocks in price to book category among its peers. It also is one of the top stocks in debt to equity category among its peers . The ratio of Price To Book to Debt To Equity for Enlivex Therapeutics is about 204.47 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Enlivex Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Enlivex Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Enlivex Debt To Equity vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Enlivex Therapeutics |
| = | 1.23 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Enlivex Therapeutics |
| = | 0.01 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Enlivex Debt To Equity Comparison
Enlivex Therapeutics is currently under evaluation in debt to equity category among its peers.
Enlivex Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Enlivex Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Enlivex Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Enlivex Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Enlivex Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel. ENLIVEX THERAPEUTI operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 50 people.
Enlivex Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Enlivex Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Enlivex Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Enlivex Therapeutics' important profitability drivers and their relationship over time.
Use Enlivex Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enlivex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enlivex Therapeutics will appreciate offsetting losses from the drop in the long position's value.Enlivex Therapeutics Pair Trading
Enlivex Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Enlivex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enlivex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enlivex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enlivex Therapeutics to buy it.
The correlation of Enlivex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enlivex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enlivex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enlivex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Enlivex Therapeutics position
In addition to having Enlivex Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate ETFs Thematic Idea Now
Real Estate ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Real Estate ETFs theme has 65 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Enlivex Stock
When determining whether Enlivex Therapeutics is a strong investment it is important to analyze Enlivex Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Enlivex Therapeutics' future performance. For an informed investment choice regarding Enlivex Stock, refer to the following important reports:Check out Investing Opportunities. For information on how to trade Enlivex Stock refer to our How to Trade Enlivex Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
To fully project Enlivex Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Enlivex Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Enlivex Therapeutics' income statement, its balance sheet, and the statement of cash flows.